Table 2.
Participants with adverse events by system
| System | trans-Resveratrol (n = 15), n (%) | Placebo (n = 15), n (%) | p value (Fisher exact test) |
|---|---|---|---|
| Infections and infestations | 6 (40) | 6 (40) | 1 |
| Nervous system disorders | 6 (40) | 6 (40) | 1 |
| Gastrointestinal disorders | 6 (40) | 5 (33.3) | > 0.9 |
| Psychiatric disorders | 5 (33.3) | 5 (33.3) | 1 |
| Injury, poisoning, or procedural complications | 4 (26.6) | 4 (26.6) | 1 |
| Weight loss | 6 (40) | 3 (20) | 0.426 |
| Musculoskeletal and connective tissue disorders | 3 (20) | 4 (26.6) | > 0.9 |
| General disorders and administrative site conditions | 2 (13.3) | 2 (13.3) | 1 |
| Respiratory, thoracic, and mediastinal disorders | 3 (20) | 3 (20) | 1 |
| Skin and subcutaneous tissue disorders | 1 (6.7) | 2 (13.3) | > 0.9 |
| Renal and urinary disorders | 1 (6.7) | 1 (6.7) | 1 |
| Vascular disorders | 1 (6.7) | 1 (6.7) | 1 |
| Cardiac disorders | 0 (0) | 0 (0) | 1 |
| Eye disorders | 0 (0) | 0 (0) | 1 |
| Metabolism and nutrition disorders | 1 (6.7) | 0 (0) | > 0.9 |
| Neoplasms benign, malignant, and unspecified | 0 | 1 (6.7) | > 0.9 |